Estimating long-term effects of disease-modifying drug therapy in multiple sclerosis patients

Multiple Sclerosis

Volumn 11, Issue 6, 2005, Pages 626-634

  Rudick, Richard A ^a   Cutter, G R ^b   Baier, M ^c   Weinstock Guttman, B ^d   Mass, M K ^e   Fisher, E ^a   Miller, D M ^a   Sandrock, A W ^f  

^a LERNER RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c Cooper Institute ^*  (United States)

^d BUFFALO GENERAL HOSPITAL   (United States)

^e OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^f BIOGEN   (United States)

Author keywords

Disease modifying drug therapy; Interferon beta; Multiple sclerosis

Indexed keywords

AZATHIOPRINE; BETA1A INTERFERON; CORTICOTROPIN; GLATIRAMER; INTERFERON BETA SERINE; METHOTREXATE; PLACEBO;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DISEASE DURATION; DRUG MECHANISM; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL SPECIALIST; MULTIPLE SCLEROSIS; OUTCOMES RESEARCH; PREDICTION; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE;

ADJUVANTS, IMMUNOLOGIC; DISABILITY EVALUATION; DISEASE PROGRESSION; FOLLOW-UP STUDIES; HUMANS; INTERFERON-BETA; MODELS, STATISTICAL; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; RANDOMIZED CONTROLLED TRIALS;

EID: 28044473653     PISSN: 13524585     EISSN: None     Source Type: Journal    
DOI: 10.1191/1352458505ms1203oa     Document Type: Article

References (20)

1. The IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993; 43: 655-61.
2. Jacobs LD, Cookfair DL, Rudick RA, Herndon RM, Richert JR, Salazar AM et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann Neurol 1996; 39: 285-94.
3. PRISMS (Prevention of Relapses and Disability by Interferon β-1a Subcutaneously in Multiple Sclerosis) Study Group. Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis. Lancet 1998; 352: 1498-504.
4. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983; 33: 1444-52.
5. Lublin FD, Reingold SC, and the National Multiple Sclerosis Society (USA) Task Force on Placebo-Controlled Clinical Trials in MS. Placebo-controlled clinical trials in multiple sclerosis: ethical considerations. Ann Neurol 2001; 49: 677-81.
6. schwid SR, Bever CT Jr. The cost of delaying treatment in multiple sclerosis. What is lost is not regained. Neurology 2001; 56: 1620.
7. The PRISMS (Prevention of Relapses and Disability by Interferon-β-1a Subcutaneously in Multiple Sclerosis) Study Group, and the University of British Columbia MS/MRI Analysis Group. PRISMS-4: long-term efficacy of interferon-β-1a in relapsing MS. Neurology 2001; 56: 1628-36.
8. Herndon RM, Jacobs LD, Coats ME, Goodkin DE, Mass MK, Richert JR et al. Results of an ongoing, open-label, safety-extension study of interferon beta-1a (Avonex) treatment in multiple sclerosis. Int J MS Care [serial online] 1999; 1: 1-6. Retrieved 5 May, 2003, from http://www.mscare.com
9. Weinshenker BG, Bass B, Rice GPA, Noseworthy J, Carriere W, Baskerville J, Ebers GC. The natural history of multiple sclerosis: a geographically based study. 1. Clinical course and disability. Brain 1989; 112: 133-46.
10. Fisher E, Rudick RA, Cutter G, Baier M, Miller D, Weinstock-Guttman B et al. Relationship between brain atrophy and disability: an 8-year follow-up study of multiple sclerosis patients. Mult Scler 2000; 6: 373-77.
11. Fisher E, Rudick RA, Simon JH, Cutter G, Baier M, Lee J-C et al. Eight-year follow-up study of brain atrophy in patients with MS. Neurology 2002; 59: 1412-20.
12. Miller DM, Rudick RA, Baier M, Cutter G, Dougherty DS, Weinstock-Guttman B et al. Factors that predict health-related quality of life in patients with relapsing-remitting multiple sclerosis. Mult Scler 2003; 9: 1-5.
13. Rudick RA, Cutter G, Baier M, Fisher E, Dougherty D, Weinstock-Guttman B et al. Use of the Multiple Sclerosis Functional Composite to predict disability in relapsing MS. Neurology 2001; 56: 1324-30.
14. Rudick RA, Fisher E, Lee JC, Duda JT, Simon J. Brain atrophy in relapsing multiple sclerosis: relationship to relapses, EDSS, and treatment with interferon β-1a. Mult Scler 2000; 6: 365-72.
15. Rudick R, Antel J, Confavreux C, Cutter G, Ellison G, Fischer J et al. Recommendations from the National Multiple Sclerosis Society Clinical Outcomes Assessment Task Force. Ann Neurol 1997; 42: 379-82.
16. Bergner M, Babbitt RA, Kressel S, Pollard WE, Gilson BS, Morris JR. The sickness impact profile: conceptual formulation and methodology for the development of a health status measure. Int J Health Serv 1976; 6: 393-415.
17. John Hopkins University. The Sickness Impact Profile User's Manual and Interpretation Guide. Baltimore, MD: Johns Hopkins University, Department of Health Policy and Management, 1996.
18. Ratzker PK, Feldman JM, Scheinberg LC, Larocca NG, Smith CR, Giesser BS, Aisen ML. Self-assessment of neurologic impairment in multiple sclerosis. J Neurol Rehab 1997; 11: 207-11.
19. Johnson KP, Brooks BR, Cohen JA, Ford CC, Goldstein J, Lisak RP et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind, placebo-controlled trial. Neurology 1995; 45: 1268-76.
20. Johnson KP, Brooks BR, Ford CC, Goodman A, Guarnaccia J, Lisak RP et al. Sustained clinical benefits of glatiramer acetate in relapsing multiple sclerosis patients observed for 6 years. Mult Scler 2000; 6: 255-66.